The cross-tumor analysis of the data for this inhibitor presented in Table 2 could be affected by the proportion of the cell lines carrying EGFR variants affecting sensitivity to afatinib and by the proportion of NSCLC cell lines in each dataset. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.